Characteristics of 91 children and adolescents undergoing allogeneic HSCT for relapsed and refractory Hodgkin lymphoma
| Parameter . | Availableno. ofpatients . | Wholeseries, n = 91 . | Conditioning regimen . | P . | |
|---|---|---|---|---|---|
| MAC, n = 40 . | RIC, n = 51 . | ||||
| Period of allogeneic HSCT (%) | 91 | <.001 | |||
| 1987-2001 | 44 (48) | 28 (70) | 16 (31) | ||
| 2002-2005 | 47 (52) | 12 (30) | 35 (69) | ||
| Male sex, % | 91 | 52 (57) | 25 (62) | 27 (53) | NS |
| Median age at diagnosis, y (range) | 91 | 13 (2-17) | 12 (2-17) | 14 (4-16) | NS |
| Stage III/IV at diagnosis (%) | 54 | 38 (70) | 21 (78) | 17 (63) | NS |
| Median time from diagnosis to allogeneic HSCT, mo (range) | 91 | 26 (6-105) | 23 (7-93) | 31 (6-105) | .02 |
| 4 or more lines of prior treatment before allogeneic HSCT (%) | 66 | 31 (47) | 8 (26) | 23 (66) | .001 |
| Prior failed autologous HSCT (%) | 91 | 40 (44) | 8 (20) | 32 (63) | <.001 |
| Median time of autologous to allogeneic HSCT, mo (range) | 37 / 50 | 14 (3-38) | 13 (8-31) | 15 (3-38) | NS |
| Median age at allogeneic HSCT, y (range) | 91 | 16 (4-18) | 14 (4-18) | 17 (8-18) | .01 |
| Disease status at allogeneic HSCT (%) | 91 | NS | |||
| CR | 24 (26) | 13 (32) | 11 (22) | ||
| PR/sensitive relapse | 30 (33) | 11 (28) | 19 (37) | ||
| Refractory relapse/progression | 32 (35) | 14 (35) | 18 (35) | ||
| Untested relapse/progression | 5 (6) | 2 (6) | 3 (6) | ||
| Chemosensitivity at HSCT (%) | 91 | NS | |||
| Sensitive disease | 54 (59) | 24 (60) | 30 (59) | ||
| Refractory disease/untested | 37 (41) | 16 (40) | 19 (41) | ||
| Karnofsky/Lansky score of 80% or less | 60 | 12 (20) | 2 (11) | 10 (24) | NS |
| Donor type (%) | 91 | NS | |||
| HLA-identical sibling* | 58 (64) | 28 (70) | 30 (59) | ||
| Other matched related | 3 (3) | 2 (5) | 1 (2) | ||
| Matched unrelated | 18 (20) | 4 (10) | 14 (27) | ||
| Mismatched related | 7 (8) | 4 (10) | 3 (6) | ||
| Mismatched unrelated | 5 (5) | 2 (5) | 3 (6) | ||
| Donor female/patient male (%) | 89 | 20 (23) | 13 (33) | 7 (14) | NS |
| Patient and donor CMV-negative (%) | 52 | 19 (36) | 10 (37) | 9 (36) | NS |
| Stem cell source, BM/PBSC, %† | 91 | 50/50 | 67/33 | 36/64 | .006 |
| Ex vivo T-cell depletion (%) | 91 | 9 (11) | 6 (16) | 3 (6) | NS |
| TBI included in conditioning (%) | 91 | 27 (30) | 16 (40) | 11 (22) | NS |
| Median follow-up of surviving patients, mo (range) | 91 | 21 (6-154) | 43 (6-154) | 16 (6-92) | .005 |
| Parameter . | Availableno. ofpatients . | Wholeseries, n = 91 . | Conditioning regimen . | P . | |
|---|---|---|---|---|---|
| MAC, n = 40 . | RIC, n = 51 . | ||||
| Period of allogeneic HSCT (%) | 91 | <.001 | |||
| 1987-2001 | 44 (48) | 28 (70) | 16 (31) | ||
| 2002-2005 | 47 (52) | 12 (30) | 35 (69) | ||
| Male sex, % | 91 | 52 (57) | 25 (62) | 27 (53) | NS |
| Median age at diagnosis, y (range) | 91 | 13 (2-17) | 12 (2-17) | 14 (4-16) | NS |
| Stage III/IV at diagnosis (%) | 54 | 38 (70) | 21 (78) | 17 (63) | NS |
| Median time from diagnosis to allogeneic HSCT, mo (range) | 91 | 26 (6-105) | 23 (7-93) | 31 (6-105) | .02 |
| 4 or more lines of prior treatment before allogeneic HSCT (%) | 66 | 31 (47) | 8 (26) | 23 (66) | .001 |
| Prior failed autologous HSCT (%) | 91 | 40 (44) | 8 (20) | 32 (63) | <.001 |
| Median time of autologous to allogeneic HSCT, mo (range) | 37 / 50 | 14 (3-38) | 13 (8-31) | 15 (3-38) | NS |
| Median age at allogeneic HSCT, y (range) | 91 | 16 (4-18) | 14 (4-18) | 17 (8-18) | .01 |
| Disease status at allogeneic HSCT (%) | 91 | NS | |||
| CR | 24 (26) | 13 (32) | 11 (22) | ||
| PR/sensitive relapse | 30 (33) | 11 (28) | 19 (37) | ||
| Refractory relapse/progression | 32 (35) | 14 (35) | 18 (35) | ||
| Untested relapse/progression | 5 (6) | 2 (6) | 3 (6) | ||
| Chemosensitivity at HSCT (%) | 91 | NS | |||
| Sensitive disease | 54 (59) | 24 (60) | 30 (59) | ||
| Refractory disease/untested | 37 (41) | 16 (40) | 19 (41) | ||
| Karnofsky/Lansky score of 80% or less | 60 | 12 (20) | 2 (11) | 10 (24) | NS |
| Donor type (%) | 91 | NS | |||
| HLA-identical sibling* | 58 (64) | 28 (70) | 30 (59) | ||
| Other matched related | 3 (3) | 2 (5) | 1 (2) | ||
| Matched unrelated | 18 (20) | 4 (10) | 14 (27) | ||
| Mismatched related | 7 (8) | 4 (10) | 3 (6) | ||
| Mismatched unrelated | 5 (5) | 2 (5) | 3 (6) | ||
| Donor female/patient male (%) | 89 | 20 (23) | 13 (33) | 7 (14) | NS |
| Patient and donor CMV-negative (%) | 52 | 19 (36) | 10 (37) | 9 (36) | NS |
| Stem cell source, BM/PBSC, %† | 91 | 50/50 | 67/33 | 36/64 | .006 |
| Ex vivo T-cell depletion (%) | 91 | 9 (11) | 6 (16) | 3 (6) | NS |
| TBI included in conditioning (%) | 91 | 27 (30) | 16 (40) | 11 (22) | NS |
| Median follow-up of surviving patients, mo (range) | 91 | 21 (6-154) | 43 (6-154) | 16 (6-92) | .005 |
BM indicates bone marrow; CMV, cytomegalovirus; CR, complete remission; HSCT, hematopoietic stem cell; MAC, myeloablative conditioning; NS, not significant; PBSC, peripheral blood stem cell; PR, partial remission; RIC, reduced-intensity conditioning; and TBI, total body irradiation.
One patient was grafted from a syngeneic donor.
One patient received BM and PBSCs.